Illumina (ILMN), a maker of DNA sequencing products, said Thursday that it has struck strategic partnerships with several big drugmakers to develop what it calls a universal next-generation sequencing-based oncology test system for cancer diagnosis. The initial strategic partners include AstraZeneca (AZN), Janssen Biotech and Sanofi (SNY). Illumina says the system will be used to conduct clinical trials for specific cancer therapies. It will help
Analysts were singing the praises of life-science giants Gilead Sciences (GILD) and Illumina (ILMN) Wednesday morning after both surged above Q1 estimates late Tuesday. Shares of both companies were up on the stock market today. Gilead’s $2.3 billion in sales for its new hepatitis C drug Sovaldi was called “one of the most impressive beats in biopharma history” by Piper Jaffray’s Joshua Schimmer, although he increased his price target by only a
With the stock market back in a confirmed uptrend, investors may want to look for big-cap companies with high Accumulation/Distributions grades that point to large institutions buying their stocks. Alexion Pharmaceuticals (ALXN), Illumina (ILMN), Micron (MU) and FleetCor Technologies (FLT) are all companies on the IBD’s Big Cap Screen of the Day that have an Accumulation/Distribution grade of A- or higher. Illumina, a maker of gene sequencing